STAXYN Drug Patent Profile
✉ Email this page to a colleague
When do Staxyn patents expire, and what generic alternatives are available?
Staxyn is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has fifty-three patent family members in thirty-eight countries.
The generic ingredient in STAXYN is vardenafil hydrochloride. There are six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Staxyn
A generic version of STAXYN was approved as vardenafil hydrochloride by TEVA PHARMS on May 3rd, 2012.
Summary for STAXYN
| International Patents: | 53 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 71 |
| Patent Applications: | 6 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for STAXYN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for STAXYN |
| What excipients (inactive ingredients) are in STAXYN? | STAXYN excipients list |
| DailyMed Link: | STAXYN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for STAXYN
Paragraph IV (Patent) Challenges for STAXYN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| STAXYN | Orally Disintegrating Tablets | vardenafil hydrochloride | 10 mg | 200179 | 1 | 2011-12-22 |
US Patents and Regulatory Information for STAXYN
STAXYN is protected by one US patents.
Patents protecting STAXYN
Pharmaceutical forms with improved pharmacokinetic properties
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for STAXYN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for STAXYN
See the table below for patents covering STAXYN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 213246 | ⤷ Try a Trial | |
| Australia | 738675 | ⤷ Try a Trial | |
| China | 100430396 | ⤷ Try a Trial | |
| Morocco | 29376 | FORMES PHARMACEUTIQUES A PROPRIETES PHARMACOCINETIQUE AMELIOREES. | ⤷ Try a Trial |
| Singapore | 160330 | PHARMACEUTICAL FORMS WITH IMPROVED PHARMACOKINETIC PROPERTIES | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
